Actually, a number of existing drugs have been shown to be effective on multiple cancers (paclitaxel and avastin are two examples). These drugs have all been approved for one condition, and have later been extended to other conditions after additional studies demonstrating effectiveness on the other conditions were performed. It's unlikely that Kevetrin will be treated any differently. However, even if Kevetrin is just used for lung cancer, it could still generate revenues of several billion dollars/year, just in the US. Other indications would be icing on the cake.
A1
News 
Market Data 
Discover 
